-
Something wrong with this record ?
A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy
G. Tisci, L. Rajsiglova, S. Bibbo, G. Ziccheddu, E. Ricciardi, E. Falvo, V. De Laurenzi, G. Sala, E. Capone, G. Colotti, A. Arcovito, N. Giacon, P. Makovický, L. Sushytskyi, P. Lukac, L. Vannucci, P. Giacomini, P. Ceci
Language English Country Netherlands
Document type Journal Article
- MeSH
- Ferritins * chemistry genetics pharmacology MeSH
- Immunotherapy * MeSH
- Humans MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Nanoparticles * chemistry MeSH
- Drug Carriers * chemistry MeSH
- Antineoplastic Agents pharmacology chemistry MeSH
- Recombinant Proteins chemistry MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
To address the challenge of drug accumulation and penetration at the tumor site(s), herein we describe a first-in-class nanocarrier containing 24 copies each of two bioactive peptides (BAPs) genetically fused in frame to the 24 N-termini of a human ferritin H-type construct, named THE-10. The two BAPs are specific for PD-L1 and integrin αVβ3/αVβ5 plus Neuropilin (iRGD) respectively, conferring immune checkpoint blockade and drug-internalization properties. In turn, the THE-10 backbone brings 48 BAPs contiguous for synergism, prolonged blood half-life, and release into the tumor microenvironment upon conditional cleavage of a metalloprotease-sensitive site. Predicted THE-10 multitasking activity was experimentally supported as follows. Size-exclusion chromatography and surface plasmon resonance demonstrated BAP cleavage/release and receptor binding (nanomolar KD). Live-cell/time-lapse imaging demonstrated 4-fold-increased internalization of naked therapeutic antibodies, mirrored by enhanced cytotoxicity of the corresponding Antibody-Drug Conjugate. Slight antitumor effects were observed in vivo by treating immune checkpoint-sensitive syngeneic mouse colorectal model with THE-10 alone. Drug boosting was instead considerable on colorectal and pancreatic tumor allografts when THE-10 was co-administered with both small and large chemotherapeutic agents, outperforming the original iRGD cyclic peptide. Thus, THE-10 may enhance target therapy, chemotherapy and immunotherapy altogether, e.g. it candidates as a multitasking, all-round, antineoplastic therapy booster.
Center for Advanced Studies and Technology Italy
Department of Biochemical Sciences Sapienza University Rome Italy
Department of Cell Biology Faculty of Science Charles University Prague Czech Republic
Fondazione Policlinico Universitario A Gemelli IRCCS Largo Agostino Gemelli 8 00168 Rome Italy
Institute of Molecular Biology and Pathology Italian National Research Council IBPM CNR Rome Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015874
- 003
- CZ-PrNML
- 005
- 20250731091316.0
- 007
- ta
- 008
- 250708s2025 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijbiomac.2025.142843 $2 doi
- 035 __
- $a (PubMed)40187454
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Tisci, Giada $u Department of Biochemical Sciences, Sapienza University, Rome, Italy
- 245 12
- $a A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy / $c G. Tisci, L. Rajsiglova, S. Bibbo, G. Ziccheddu, E. Ricciardi, E. Falvo, V. De Laurenzi, G. Sala, E. Capone, G. Colotti, A. Arcovito, N. Giacon, P. Makovický, L. Sushytskyi, P. Lukac, L. Vannucci, P. Giacomini, P. Ceci
- 520 9_
- $a To address the challenge of drug accumulation and penetration at the tumor site(s), herein we describe a first-in-class nanocarrier containing 24 copies each of two bioactive peptides (BAPs) genetically fused in frame to the 24 N-termini of a human ferritin H-type construct, named THE-10. The two BAPs are specific for PD-L1 and integrin αVβ3/αVβ5 plus Neuropilin (iRGD) respectively, conferring immune checkpoint blockade and drug-internalization properties. In turn, the THE-10 backbone brings 48 BAPs contiguous for synergism, prolonged blood half-life, and release into the tumor microenvironment upon conditional cleavage of a metalloprotease-sensitive site. Predicted THE-10 multitasking activity was experimentally supported as follows. Size-exclusion chromatography and surface plasmon resonance demonstrated BAP cleavage/release and receptor binding (nanomolar KD). Live-cell/time-lapse imaging demonstrated 4-fold-increased internalization of naked therapeutic antibodies, mirrored by enhanced cytotoxicity of the corresponding Antibody-Drug Conjugate. Slight antitumor effects were observed in vivo by treating immune checkpoint-sensitive syngeneic mouse colorectal model with THE-10 alone. Drug boosting was instead considerable on colorectal and pancreatic tumor allografts when THE-10 was co-administered with both small and large chemotherapeutic agents, outperforming the original iRGD cyclic peptide. Thus, THE-10 may enhance target therapy, chemotherapy and immunotherapy altogether, e.g. it candidates as a multitasking, all-round, antineoplastic therapy booster.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a imunoterapie $7 D007167
- 650 _2
- $a myši $7 D051379
- 650 12
- $a ferritiny $x chemie $x genetika $x farmakologie $7 D005293
- 650 12
- $a nosiče léků $x chemie $7 D004337
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 12
- $a nanočástice $x chemie $7 D053758
- 650 _2
- $a protinádorové látky $x farmakologie $x chemie $7 D000970
- 650 _2
- $a rekombinantní proteiny $x chemie $7 D011994
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rajsiglova, Lenka $u Laboratory of Immunotherapy, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic; Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic
- 700 1_
- $a Bibbo, Sandra $u Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), Italy
- 700 1_
- $a Ziccheddu, Giovanna $u Translational Oncology Unit, IRCCS National Cancer Institute Regina Elena, Via Elio Chianesi 53, Rome, Italy
- 700 1_
- $a Ricciardi, Elena $u Translational Oncology Unit, IRCCS National Cancer Institute Regina Elena, Via Elio Chianesi 53, Rome, Italy
- 700 1_
- $a Falvo, Elisabetta $u Institute of Molecular Biology and Pathology, Italian National Research Council IBPM-CNR, Rome, Italy
- 700 1_
- $a De Laurenzi, Vincenzo $u Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), Italy
- 700 1_
- $a Sala, Gianluca $u Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), Italy. Electronic address: g.sala@unich.it
- 700 1_
- $a Capone, Emily $u Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), Italy
- 700 1_
- $a Colotti, Gianni $u Institute of Molecular Biology and Pathology, Italian National Research Council IBPM-CNR, Rome, Italy
- 700 1_
- $a Arcovito, Alessandro $u Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Rome, Italy; Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy
- 700 1_
- $a Giacon, Noah $u Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Rome, Italy
- 700 1_
- $a Makovický, Peter $u Institute of Histology and Embryology, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava-Vítkovice, Czech Republic
- 700 1_
- $a Sushytskyi, Leonid $u Laboratory of Immunotherapy, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic; Department of Carbohydrates and Cereals, Faculty of Food and Biochemical Technology, University of Chemistry and Technology in Prague, Technická 5, 166 28 Prague, Czech Republic
- 700 1_
- $a Lukac, Pavol $u Laboratory of Immunotherapy, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic; Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic
- 700 1_
- $a Vannucci, Luca $u Laboratory of Immunotherapy, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Giacomini, Patrizio $u UOSD Medicina di Precisione in Senologia, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Largo Agostino Gemelli 8, Rome, Italy
- 700 1_
- $a Ceci, Pierpaolo $u Institute of Molecular Biology and Pathology, Italian National Research Council IBPM-CNR, Rome, Italy; Thena Biotech, Latina, Italy. Electronic address: pierpaolo.ceci@cnr.it
- 773 0_
- $w MED00002295 $t International journal of biological macromolecules $x 1879-0003 $g Roč. 309, č. Pt 1 (2025), s. 142843
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40187454 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091311 $b ABA008
- 999 __
- $a ok $b bmc $g 2366600 $s 1252999
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 309 $c Pt 1 $d 142843 $e 20250403 $i 1879-0003 $m International journal of biological macromolecules $n Int J Biol Macromol $x MED00002295
- LZP __
- $a Pubmed-20250708